Clinical trials
Hepatitis D, Chronic clinical trials
Below are recruiting hepatitis d, chronic clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT04166266Recruiting
Study of adults with hepatitis D and hepatitis B coinfection
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
AngersAges 18 years+ - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT06051045Recruiting
Bulevirtide for chronic hepatitis B and D
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
StockholmAges 18 years+ - NCT06122285Recruiting
Bulevirtide for chronic hepatitis delta
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Milan, MIAges 18 years+ - NCT07200908RecruitingPhase 3
Comparing brelovitug and bulevirtide for hepatitis delta
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
GrazAges 18–99 - NCT07491848Recruiting
Mouth health study for hepatitis B and D patients
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
CraiovaAges 18 years+ - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT06779058Recruiting
Liver stiffness testing for hepatitis B patients
This trial uses MR elastography (a special MRI) to measure liver stiffness and check for fibrosis (scarring) without a needle biopsy. It may help guide treatment for chronic hepatitis B.
Shenyang, LiaoningAges 18–80 - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65 - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT05922306RecruitingEarly Phase 1
Testing continuous vs pulsed treatment for chronic hepatitis B
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
Hefei, AnhuiAges 18–60 - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT05182463RecruitingPhase 4
Peginterferon test for inactive chronic hepatitis B
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
Guangzhou, GuangdongAges 18–60 - NCT06248580Recruiting
Finding HDV in Turkey Study
This trial is looking for adults in Turkey who have had a hepatitis B infection (HBsAg positive) for at least 6 months. The goal is to see if they also have a hepatitis D virus (HDV) infection. This may help doctors better understand and treat these infections.
AnkaraAges 18 years+ - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+ - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Palo Alto, CaliforniaAges 18–65
Hear when a new Hepatitis D, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis d, chronic?
- Yes. Clin2 currently lists 47 recruiting hepatitis d, chronic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis d, chronic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis d, chronic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.